ProfileGDS5678 / 1450026_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 91% 92% 92% 93% 89% 86% 88% 88% 92% 93% 91% 92% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.2001190
GSM967853U87-EV human glioblastoma xenograft - Control 27.4696191
GSM967854U87-EV human glioblastoma xenograft - Control 37.6306992
GSM967855U87-EV human glioblastoma xenograft - Control 47.7218792
GSM967856U87-EV human glioblastoma xenograft - Control 57.9357293
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7299789
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3602486
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7884588
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8529788
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.6013792
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.8168893
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4483391
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.5491692
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5853792